; the failure to furnish any notification, information, material, or report required under section 587R; or the failure to comply with an order issued under section 587R. . (b) Penalties Section 303(f)(1) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 333(f)(1) ) is amended— (1) in subparagraph (A), by inserting or in vitro clinical tests after devices ; and (2) in subparagraph (B)(i)— (A) by inserting , or 587J or 587L, after 520(f) ; and (B) by inserting , or who violates section 587M(b) with respect to a correction report after risk to public health . (c) Seizure Section 304 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 334 ) is amended— (1) in subsection (a)(2)— (A) by striking and before (E) Any ; and (B) by inserting , and (F) Any adulterated or misbranded in vitro clinical test after tobacco product ; (2) in subsection (d)(1), by inserting in vitro clinical test, after device, ; and (3) in subsection (g)— (A) in paragraph (1), by inserting , in vitro clinical test, after device each place it appears; and (B) in paragraph (2)— (i) in subparagraph (A), by inserting , in vitro clinical test, after device ; and (ii) in subparagraph (B), by inserting or in vitro clinical test after device each place it appears. (d) Debarment, temporary denial of approval, and suspension Section 306 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 335a ) is amended by adding at the end the following: (n) In vitro clinical tests